Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million on April 11, 2024. The total potential consideration of up to $45 million includes up-front consideration of $35 million in a combination of cash and shares in Century. Future milestones have the potential of generating further consideration and if received in full will result in a further $10 million in consideration.

For its 22% ownership position in Clade, Syncona anticipates up-front consideration at closing to be $9.3 million, an estimated £16.1 million write down from the 31 December 2023 valuation of £23.5 million.